Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib in ALK+ Advanced NSCLC (CUBIK)
NCT04223596Phase 2Active, not recruiting
- Sponsor
- Fundación GECP
- Start
- May 2020
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brigatinib in non-small cell lung cancer (NSCLC), sponsored by Fundación GECP. Started May 2020; status: active, not recruiting.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04223596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04223596.